{
  "ticker": "PCK",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02965454",
  "id": "02965454",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250703",
  "time": "0901",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250703/pdf/06lf005dbb9sxm.pdf",
  "summary": "### Summary (Quarterly Sales Update):  \n\n- **Net Contracted Licences**: Increased 9% to **110,000**.  \n- **Contracted ARR**: Up 10% to **A$5.4 million**.  \n- **Net Licence Retention Rate**: **106%** (indicating customer expansion).  \n- **New Clients**: Secured in **UK, Australia, and Canada** with mixed 1/2-year agreements.  \n- **Global Pain Assessments**: Exceeded **12 million**.  \n- **Scottish Inspectorate Validation**: Positive outcomes, potential for further adoption in national healthcare frameworks.  \n\n*No material capital markets actions (e.g., raising, timetable) identified.*",
  "usage": {
    "prompt_tokens": 1675,
    "completion_tokens": 145,
    "total_tokens": 1820,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-02T23:14:58.371899"
}